SMi Presents the 16th Annual Conference: Parallel Trade 2022

SMi Group21 - 22 March 2022, Virtual Conference.
SMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

The 2022 event will be more significant than ever before due to the transition period after Brexit coming to an end. As such, the UK will no longer be part of the EU free market. This will mean increased medicines prices, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment, exhaustion of rights will cease to apply to the UK, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution.

This conference will bring together industry experts to discuss the challenges and drivers of the industry, including the EU regulatory landscape and the impact of the Brexit and the Pandemic together. The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states.

Book on or before 28th January to receive £100 off the conference price

Register online today at http://parallel-trade.com or call Daniele Moreschi, Director on +44 (0)20 7827 6050 or email This email address is being protected from spambots. You need JavaScript enabled to view it.

Co-Chairs For 2022

  • Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP
  • Eric Noehrenberg, Vice President and Global Head of Market Access and Goverment Affairs, Corcym

Key Speakers Include

  • Martin Howe, Queen's Counsel, 8 New Square
  • Shabnam Hanassab, Engagement Manager, iQvia
  • Tushar Patel, Technical Director, Key Pharmaceuticals Ltd
  • Dermot Glynn, Senior Advisor, Europe Economics
  • Stefan Enchelmaier, Professor of European and Comparative Law, Tutor in Jurisprudence, lincoln College, GB-Oxford
  • Hynek Valerián, Group Parallel Trade Manager, Dr.Max group
  • Jackie Mulryne, Partner, Arnold & Porter
  • Peter Bogaert, Managing Partner, Covington & Burling
  • ... and many more

Key Benefits of attending

  • Discover the impact of COVID-19 on Parallel trade as countries begin to release restrictions. How has the sector been influenced?
  • Engage in discussions on the growth within parallel trade over the past year at the only Parallel Trade specific conference within the EU.
  • Discuss the impact on UK parallel trade following Brexit, through the eyes of regulators, the pharmaceutical industry and academics
  • Develop further understanding of the rules and regulation changes over the past 12 months, Parallel Trade, where are we now?

Who should attend

  • Vice President/ Heads of/General Managers:
  • International Trade and Relations
  • Supply Chain Development - Brexit
  • Brexit Implementation
  • Market Access
  • Supply Chain Manager
  • Parallel trade reporting
  • Regulatory Affairs
  • IP
  • Purchasing
  • Policy Patent Operations
  • European Affairs
  • Supply and Demand
  • Attorney
  • Distribution

SMi Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. For details contact Andrew Gibbons on +44 (0) 20 7827 6156 or email This email address is being protected from spambots. You need JavaScript enabled to view it.

Plus, Two post-conference interactive workshops

Workshop A : Parallel Trade let's talk details

Workshop Leader: Tushar Patel, Technical Director, Key Pharmaceuticals Ltd

Workshop Overview: This workshop will discuss all of the main topics within parallel trade, looking back to understand the future. There will be highlights on the history of parallel imports and how this works with the UK. The workshop will also highlight parallel trade and Brexit, discussing where we are now and what strategies are currently being used, do they give parallel traders and advantage and how will Brexit effect parallel trade in the long term. The workshop will highlight the challenges and successes of the industry and will also allow for open discussion on the future of this industry.

This workshop will allow you to:

  • Discover the future of parallel trade, based on the history we have
  • Understand where we are now, how has Brexit effected the parallel trade industry
  • Interact with industry professionals with Q&A sessions.
  • Speak with Tushar Patel about current trading models and the specific challenges for different industry professionals.

Workshop B: The Case Law of Parallel Imports

Workshop Leader: Stefan Enchelmaier, Professor of European and Comparative Law, Tutor in Jurisprudence, Lincoln College, GB-Oxford

Workshop Overview: This workshop will allow attendees to discuss and build their understanding of case law within Parallel Trade. With interactive sessions, opportunities to question and learn, this workshop will discuss national IP rights and the trade of COVID 19 vaccines. There will be highlights of Professor Stefan Enchelmaier's work and case studies, focusing on re-packaging and intellectual property.

This workshop will allow you to:

  • Discover when parallel trade is permissible
  • Engage in interactive sessions about case law with a focus on packaging
  • Discuss potential cases with Stefan and understand develop your understanding of the movement of free goods.

For further information and to register, please visit:
http://parallel-trade.com

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...